Isomorphic Labs raised $2.1 billion in Series B funding. The capital will be used for the continued development and deployment of Isomorphic Labs' AI drug design engine (IsoDDE), accelerating and expanding its pipeline of therapeutic programs towards the clinic. Additionally, the funding will support their existing hiring targets by integrating world-class AI, engineering, drug design, and clinical talent across our sites. This global scale is crucial to Isomorphic Labs' long-term vision of applying AI-driven breakthroughs to the most complex biological and medical challenges and addressing the global burden of disease.

$220M: Series D for Inobrodib in Multiple Myeloma Trials 

CellCentric announced the completion of an oversubscribed $220 million Series D financing. Proceeds will support the advancement of inobrodib, a first-in-class orally administered drug for relapsed or refractory multiple myeloma, through pivotal clinical development studies, including continued enrollment of the company’s recently initiated phase 2 DOMMINO-1 study in the U.K. and U.S. and initiation of the global phase 3 DOMMINO-2 trial in the second half of 2026. Capital raised will also fund expansion of inobrodib into additional combination and maintenance treatment settings.

$165M: Crossover Financing for Anti-TSLP Antibody 

Windward Bio raised a $165 million crossover financing to push its long-acting anti-TSLP antibody into phase 3. The cash infusion is meant to accelerate the development of the company’s lead candidate, a twice-yearly anti-TSLP agent dubbed WIN378, which is currently nearing an initial readout from a phase 2 dose-ranging portion of the phase 2/3 Polaris trial in asthma. The company now expects to launch the first phase 3 study in the fourth quarter of 2026, with another phase 2 in chronic obstructive pulmonary disease scheduled to start before the end of June. With the new funds, Windward also aims to push its long-acting TSLPxIL-13 bispecific candidate, WIN027, into “multiple proof-of-concept studies across respiratory and dermatology indications” starting in the coming fourth quarter.

$125M: Series A for Advance Immunology Pipeline 

Coultreon Biopharma (formerly Onco3R Therapeutics) announced the closing of an oversubscribed $125 million Series A financing round. The financing will support the further clinical development of Coultreon’s lead immunology program, COL-5671 (formerly O3R-5671), a highly selective, oral once-daily SIK3 inhibitor currently in phase 1 studies. The company plans to advance COL-5671 into psoriasis and ulcerative colitis phase 2 clinical trials, with potential to demonstrate clinical proof-of-concept in 2027.

$122M: Series B for In Vivo CAR Treatments 

CREATE Medicines closed its $122 million Series B financing. The funding will support advancement of the company’s clinical pipeline across autoimmune disease and oncology. To date, CREATE has dosed more than 50 patients across its in vivo CAR clinical programs—the largest clinical dataset in the field—generating the translational foundation that informs development across both autoimmune disease and oncology. The company's proprietary mRNA-LNP platform programs immune cells directly inside the body, enabling a rapid, iterative product engine designed to compress concept-to-clinic timelines.

$97M: Series A for Gene Therapy Expansion 

Latus Bio announced the closing of a $97 million Series A financing. The proceeds will fund operations through key milestones, including initial clinical data from the company’s two most advanced programs. These include LTS-201 for Huntington’s disease and LTS-101 for late-infantile neuronal ceroid lipofuscinosis type 2 disease. Proceeds will also advance additional preclinical programs that utilize the company’s proprietary AAV discovery platform.

$83M: Series A for First-in-Class Pan-Gamma Delta T Cell Engagers 

Cytospire Therapeutics closed an oversubscribed $83 million Series A financing. Cytospire will use the proceeds to advance its pipeline of first-in-class pan-gamma delta T cell engagers, including its lead program, CYT X300, which is currently being advanced through IND-enabling preclinical studies and GMP manufacturing. A first-in-human clinical study is being planned to evaluate CYT X300 as a treatment for EGFR-positive solid tumors, such as colorectal, head and neck, and non-small cell lung cancers.

$55M: Series B for Quantum Healthcare Platform 

NVision announced a $55 million Series B financing round. The proceeds will be used to expand from quantum sensing into quantum computing. The company plans to combine quantum computing for drug design with the company’s POLARIS quantum-enhanced MRI platform for therapy validation. POLARIS uses quantum technology to boost the MRI signal of sugar-based imaging agents by orders of magnitude, enabling real-time measurement of metabolism on standard MRI systems. This allows researchers to assess treatment response within hours to days based on disease biology, rather than relying on traditional imaging that can take up to months to show changes in morphology. Building on the quantum molecular approach behind POLARIS, NVision is also extending its platform into quantum computation. While developing its MRI signal enhancement technology, NVision discovered a new class of organic molecule-based qubits.  

$48M: Series A for Novel Microbiome Therapeutics  

Kanvas Biosciences raised a $48 million Series A funding. The funding will be used to conduct clinical trials for the lead drug candidate in the company’s immuno-oncology program, KAN-001, and advance commercial partnerships that leverage Kanvas’ spatial imaging and manufacturing platform for next generation live biotherapeutic product (LBP) development.

$40M: Series A for Molecular Glue Degrader 

Degron Therapeutics announced the closing of a $40 million Series A extension. The financing will advance Degron's lead program, DEG6498—a first-in-class Human antigen R molecular glue degrader—which entered the clinic in late 2025 with first patient dosed in November. The program, which targets a previously undruggable RNA-binding protein with key roles in driving cancer, inflammation, and metabolic disorders, is currently in dose escalation in a phase 1 study in patients with advanced solid tumors.

$20M: Series C for Parkinson’s Disease Trial 

Cerevance announced the closing of a $20 million Series C financing round and the completion of patient enrollment in the pivotal phase 3 ARISE trial evaluating solengepras in Parkinson’s disease. The ARISE trial enrolled 341 patients across the United States, Europe, United Kingdom, and Australia, and is assessing solengepras as an adjunctive therapy to levodopa and other standard-of-care Parkinson’s medications in patients who experience motor fluctuations, including daily OFF periods. Solengepras is a potential first-in-class, once-daily oral therapy that works through a fundamentally different mechanism than existing Parkinson’s treatments. By targeting the GPR6 receptor rather than the dopamine system, solengepras is designed to reduce OFF periods, the hours each day when symptoms reoccur despite medication.  

$13M: Seed Financing for Next-Gen mRNA Medicines 

ParcelBio raised $13 million in seed financing. The financing will support development of ParcelBio’s proprietary Amplified and Prolonged EXpression mRNA (APEXm) platform and advance its pipeline, including its lead in vivo CAR-T program for autoimmune disease, as well as additional programs in oncology and encoded protein therapeutics. The APEXm platform engineers RNA molecules to actively recruit the cell’s native RNA-stabilizing machinery, enabling significantly higher and more durable protein expression. This approach leads to a step-change in biological performance, reaching therapeutic thresholds that have historically been out of reach for mRNA.

$4.75M: Seed Financing for Synaptic Preservation 

Violet Therapeutics closed a $4.75 million seed financing. The financing will support the advancement of Violet’s lead small molecule program targeting EphB3 through key IND enabling activities. The program has the potential to deliver a first-in-class therapeutic that can halt and potentially reverse cognitive decline to restore lost mental functions associated with neurodegenerative diseases and aging via the novel mechanism of glial-mediated synaptic preservation. 

$2.5M: Seed Financing for Anti-Infectives and Cancer Therapeutics 

Stoked Bio closed a $2.5 million seed financing round. This financing round will support the continued development of anti-infectives and programs treating conditions of the microbiome, the first cancer program for Glioblastoma, and a novel treatment approach to improve symptoms of Parkinson's Disease.